Incyte to buy blood disorder drug in possibly $2B deal

Incyte Acquires Vega Therapeutics for $1.25B Upfront

Incyte, a pharmaceutical company specializing in blood diseases and cancers, has announced its agreement to acquire Vega Therapeutics, a subsidiary of Star Therapeutics. The deal involves an upfront payment of $1.25 billion, with potential additional payments of up to $750 million contingent on achieving certain sales goals, bringing the total potential value to $2 billion. This acquisition grants Incyte control over VGA039, an experimental, first-in-class medicine currently in late-stage testing. VGA039 is being developed as a once-monthly, under-the-skin injection for von Willebrand disease, the most common inherited bleeding disorder, offering a potentially more convenient preventative treatment option compared to existing intravenous therapies.

• The acquisition of Vega Therapeutics and its lead asset, VGA039, is a strategic move for Incyte to secure new growth drivers. With the primary patents for Incyte's major revenue-generating drug, Jakafi, nearing expiration, CEO Bill Meury emphasized that this deal is crucial for defining the company's next chapter and building a top-tier growth company for the future.
• VGA039 is highlighted as a "first-in-class" therapy with "compelling early data" and a "manageable development path." Its once-monthly, subcutaneous injection formulation offers a significant advantage over current preventative treatments for von Willebrand disease, which typically require intravenous infusions multiple times a week, potentially enhancing patient adherence and quality of life.
• The financial structure of the deal includes an initial $1.25 billion payment, with an additional $750 million in potential milestone payments tied to sales performance, totaling up to $2 billion. Despite the substantial investment, Incyte's shares experienced only a minor dip of less than 1% in late Monday morning trading, suggesting a relatively stable market reception to the acquisition.

The Limitations of Current von Willebrand Disease Treatments

Current von Willebrand disease treatments face significant limitations that impact patient outcomes across different disease subtypes and clinical scenarios. These constraints span from drug efficacy issues to safety concerns and diagnostic challenges. The limitations create substantial unmet medical needs, particularly for patients with more severe disease forms and specific bleeding manifestations.

• Desmopressin shows limited efficacy across disease subtypes, with most type 2 VWD patients and all type 3 patients failing to respond consistently, while approximately 50% of patients with quantitative VWF defects due to increased clearance demonstrate poor response rates

• Plasma-derived factor concentrates carry inherent safety risks, including theoretical disease transmission, hypersensitivity reactions, inhibitor development, and thrombotic complications, with fresh-frozen plasma and cryoprecipitate retaining small but persistent infection transmission risks

• Bleeding time correction remains inconsistent even with effective plasma concentrates, often requiring adjunctive platelet concentrates or desmopressin when poor bleeding time correction associates with continued hemorrhage

• Menorrhagia management represents the greatest unmet need, affecting 61.8% of women with VWD, with current hormonal and non-hormonal therapies limited by ineffectiveness and intolerance, while VWF replacement serves as third-line therapy in only 1.6% of cases

• Mucosal and joint bleeding remain problematic in clinically severe disease, with patients often unresponsive to standard treatments like desmopressin or antifibrinolytic therapy, necessitating VWF replacement with limited prophylaxis data available

• Diagnostic and classification challenges persist despite pathophysiological advances, complicated by clinical expression variability, laboratory method limitations, and expensive commercial VWF propeptide assays that are prohibitive for developing countries

• Evidence gaps exist for special populations, including limited data for elderly patients in clinical trials, insufficient surgical outcomes data for mild type 1 VWD, and ongoing investigation of recombinant VWF use in surgical patients, pregnant women, and children

The Global Burden of von Willebrand Disease

Recent genetic-based epidemiological studies provide the most comprehensive global prevalence estimates for von Willebrand disease (VWD) to date. Analysis of 807,162 subjects from the Genome Aggregation Database (gnomAD-v4.1) in 2026 revealed substantially higher prevalence rates than previously reported, with type 1 VWD affecting 10.6 per 1,000 individuals globally, type 2A affecting 1.3 per 1,000, type 2B affecting 1.7 per 1,000, and type 2M affecting 1.5 per 1,000 individuals. For the recessive forms, type 2N VWD occurs in 33.9 cases per million, while type 3 VWD affects 1.3 cases per million, increasing to 1.8 per million when structural variants and copy number variants are included.

Population-based studies consistently estimate VWD prevalence between 0.8% and 1.6%, with approximately 1 in 1,000 individuals carrying clinically significant VWD phenotypes. However, a striking diagnostic gap persists globally, as registry-reported prevalence averages only 25.6 per million cases. Earlier systematic review data from 2024 demonstrated wide variability in reported prevalence, ranging from 108.9 to 2,200 per 100,000 in population-based studies and from 0.3 to 16.5 per 100,000 in referral-based studies, reflecting differences in diagnostic approaches and healthcare access.

The prevalence of VWD varies significantly across ethnic groups, with type 3 VWD showing particular geographic variation correlated with the frequency of consanguineous marriages in different populations. These updated genetic prevalence data suggest that pathogenic VWF variants may be significantly more common than the traditional 1% estimate, indicating that a substantial number of patients remain undiagnosed worldwide. No specific global incidence data for VWD were available in current literature sources.

VGA039: A Differentiated Approach to von Willebrand Disease

Current standard-of-care treatments for von Willebrand disease have remained largely unchanged for decades, with desmopressin (DDAVP) serving as the primary treatment for type 1 VWD patients, demonstrating efficacy in approximately 80% of cases. For patients unresponsive to DDAVP or those with more severe disease subtypes, virally-inactivated factor VIII/von Willebrand factor concentrates represent the mainstay therapy. Clinical studies have demonstrated excellent to good efficacy rates of 92-93% for these concentrates in managing bleeding episodes and surgical procedures, though they remain costly and require intravenous administration.

Investigational therapies under development aim to address significant unmet medical needs in VWD treatment. New von Willebrand factor products with minimal factor VIII content are being evaluated to mitigate concerns about sustained high factor VIII levels and potential thrombotic complications from repeated infusions. These newer concentrates are designed with structures that more closely resemble intact normal plasma VWF and appear promising in early evaluations, though the optimal treatment product has not yet been produced and standardized assays for VWF in concentrates still need establishment.

Emerging therapeutic approaches represent a paradigm shift from traditional replacement therapy. Gene therapy and CRISPR-Cas9 gene editing technologies are being explored, though the wide variety of pathogenic VWF mutations and the large size of the VWF gene present significant challenges for developing broadly applicable treatments. A novel bispecific single-domain antibody (KB-V13A12) has shown promise in preclinical studies, demonstrating sustained 2-fold increases in VWF antigen levels for up to ten days following single subcutaneous administration and normalizing hemostasis in mouse models. Despite these advances, innovation in VWD therapeutic strategies has essentially stalled, and patients continue to experience reduced quality of life, highlighting the critical need for new treatment modalities.